LENZ Therapeutics, Inc. (LENZ)
NASDAQ: LENZ · Real-Time Price · USD
9.67
+0.32 (3.42%)
Apr 2, 2026, 4:00 PM EDT - Market closed
Company Description
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.
Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021.
The company was founded in 2013 and is headquartered in Solana Beach, California.
LENZ Therapeutics, Inc.
| Country | United States |
| Founded | 2019 |
| IPO Date | Jun 25, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 152 |
| CEO | Evert Schimmelpennink |
Contact Details
Address: 201 Lomas Santa Fe Drive, Suite 300 Solana Beach, California 92075 United States | |
| Phone | 858 925 7000 |
| Website | lenz-tx.com |
Stock Details
| Ticker Symbol | LENZ |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 1815776 |
| CUSIP Number | 52635N103 |
| ISIN Number | US52635N1037 |
| Employer ID | 84-4867570 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Evert B. Schimmelpennink | President, Chief Executive Officer, Secretary and Director |
| James W. McCollum | Co-Founder and Director |
| Daniel R. Chevallard CPA | Chief Financial Officer |
| Marc G. Odrich M.D. | Chief Medical Officer |
| Domenick Porfidia | Vice President of Sales |
| David Choromanski | Vice President of Marketing |
| Shawn Olsson | Chief Commercial Officer |
| Melissa Rosness | Senior Vice President of Manufacturing Operations |
| Kris Gambelin | Senior Vice President of Regulatory and Clincal Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 24, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 24, 2026 | 10-K | Annual Report |
| Mar 24, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 5, 2026 | SCHEDULE 13G/A | Filing |
| Jan 21, 2026 | SCHEDULE 13G/A | Filing |
| Jan 7, 2026 | 8-K | Current Report |
| Dec 12, 2025 | 8-K | Current Report |
| Nov 17, 2025 | 144 | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |